Ruili New Materials: Termination of Weinan Ruili Pharmaceutical Co., Ltd. API Project

Ruilian New Materials announced that the company held the second interim meeting of the third board of directors and the second interim meeting of the third board of supervisors on July 28, 2025. The meeting approved the "Proposal on Terminating Some Fundraising Investment Projects", agreeing to terminate the raw material project of Weinan Ruilian Pharmaceutical Co., Ltd. By June 30, 2025, a total of 179 million yuan has been invested in the raw material project from the raised funds, with a contract awaiting payment of 6.11 million yuan. The remaining 216 million yuan from the raised funds will continue to be held in the original designated account and managed in accordance with the company's relevant regulations. In the future, the company will promptly seek new projects with strong profitability and development prospects, use the remaining funds wisely, strictly follow the regulatory requirements for fund use, conduct relevant review procedures, and promptly disclose information to ensure the safety and effective use of the raised funds.